-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Enterovirus -X- _ O
71 -X- _ O
( -X- _ O
EV71 -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
highly -X- _ O
infectious -X- _ O
agent -X- _ O
that -X- _ O
plays -X- _ O
an -X- _ O
etiological -X- _ O
role -X- _ O
in -X- _ O
hand -X- _ O
, -X- _ O
foot -X- _ O
, -X- _ O
and -X- _ O
mouth -X- _ O
disease. -X- _ O
It -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
severe -X- _ O
neurological -X- _ O
complications -X- _ O
and -X- _ O
has -X- _ O
caused -X- _ O
significant -X- _ O
mortalities -X- _ O
in -X- _ O
recent -X- _ O
large-scale -X- _ O
outbreaks. -X- _ O
Currently -X- _ O
, -X- _ O
no -X- _ O
effective -X- _ O
vaccine -X- _ O
or -X- _ O
specific -X- _ O
clinical -X- _ O
therapy -X- _ O
is -X- _ O
available -X- _ O
against -X- _ O
EV71. -X- _ O
METHODS -X- _ O
: -X- _ O
Unmodified -X- _ B-Intervention
21 -X- _ I-Intervention
nucleotide -X- _ I-Intervention
small -X- _ I-Intervention
interfering -X- _ I-Intervention
RNAs -X- _ I-Intervention
( -X- _ I-Intervention
siRNAs -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
classic -X- _ I-Intervention
2 -X- _ I-Intervention
( -X- _ I-Intervention
′ -X- _ I-Intervention
) -X- _ I-Intervention
-modified -X- _ I-Intervention
( -X- _ I-Intervention
2 -X- _ I-Intervention
( -X- _ I-Intervention
′ -X- _ I-Intervention
) -X- _ I-Intervention
-O-methylation -X- _ I-Intervention
or -X- _ I-Intervention
2 -X- _ I-Intervention
( -X- _ I-Intervention
′ -X- _ I-Intervention
) -X- _ I-Intervention
-fluoro -X- _ I-Intervention
modification -X- _ I-Intervention
) -X- _ I-Intervention
siRNAs -X- _ I-Intervention
were -X- _ O
designed -X- _ O
to -X- _ O
target -X- _ O
highly -X- _ O
conserved -X- _ O
5 -X- _ B-Patient
( -X- _ I-Patient
′ -X- _ I-Patient
) -X- _ I-Patient
untranslated -X- _ I-Patient
region -X- _ I-Patient
( -X- _ I-Patient
UTR -X- _ I-Patient
) -X- _ I-Patient
of -X- _ I-Patient
the -X- _ I-Patient
EV71 -X- _ I-Patient
genome -X- _ I-Patient
and -X- _ O
employed -X- _ O
as -X- _ O
anti-EV71 -X- _ O
agents. -X- _ O
Real-time -X- _ O
TaqMan -X- _ O
RT-PCR -X- _ O
, -X- _ O
western -X- _ O
blot -X- _ O
analysis -X- _ O
and -X- _ O
plaque -X- _ O
assays -X- _ O
were -X- _ O
carried -X- _ O
out -X- _ O
to -X- _ O
evaluate -X- _ O
specific -X- _ O
viral -X- _ O
inhibition -X- _ O
by -X- _ O
the -X- _ O
siRNAs. -X- _ B-Intervention
RESULTS -X- _ O
: -X- _ O
Transfection -X- _ B-Outcome
of -X- _ I-Outcome
rhabdomyosarcoma -X- _ I-Outcome
( -X- _ I-Outcome
RD -X- _ I-Outcome
) -X- _ I-Outcome
cells -X- _ I-Outcome
with -X- _ I-Outcome
siRNAs -X- _ I-Outcome
targeting -X- _ I-Outcome
the -X- _ I-Outcome
EV71 -X- _ I-Outcome
genomic -X- _ I-Outcome
5 -X- _ I-Outcome
( -X- _ I-Outcome
′ -X- _ I-Outcome
) -X- _ I-Outcome
UTR -X- _ I-Outcome
significantly -X- _ I-Outcome
delayed -X- _ I-Outcome
and -X- _ I-Outcome
alleviated -X- _ I-Outcome
the -X- _ I-Outcome
cytopathic -X- _ I-Outcome
effects -X- _ I-Outcome
of -X- _ I-Outcome
EV71 -X- _ I-Outcome
infection -X- _ I-Outcome
, -X- _ I-Outcome
increased -X- _ I-Outcome
cell -X- _ I-Outcome
viability -X- _ I-Outcome
in -X- _ I-Outcome
EV71-infected -X- _ I-Outcome
RD -X- _ I-Outcome
cells. -X- _ I-Outcome
The -X- _ O
inhibitory -X- _ O
effect -X- _ O
on -X- _ O
EV71 -X- _ O
replication -X- _ O
was -X- _ O
sequence-specific -X- _ O
and -X- _ O
dosage-dependent -X- _ O
, -X- _ O
with -X- _ O
significant -X- _ B-Outcome
corresponding -X- _ I-Outcome
decreases -X- _ I-Outcome
in -X- _ I-Outcome
viral -X- _ I-Outcome
RNA -X- _ I-Outcome
, -X- _ I-Outcome
VP1 -X- _ I-Outcome
protein -X- _ I-Outcome
and -X- _ I-Outcome
viral -X- _ I-Outcome
titer. -X- _ I-Outcome
Appropriate -X- _ I-Outcome
2 -X- _ I-Outcome
( -X- _ I-Outcome
′ -X- _ I-Outcome
) -X- _ I-Outcome
-modified -X- _ I-Outcome
siRNAs -X- _ I-Outcome
exhibited -X- _ I-Outcome
similar -X- _ I-Outcome
RNA -X- _ I-Outcome
interference -X- _ I-Outcome
( -X- _ I-Outcome
RNAi -X- _ I-Outcome
) -X- _ I-Outcome
activity -X- _ I-Outcome
with -X- _ I-Outcome
dramatically -X- _ I-Outcome
increased -X- _ I-Outcome
serum -X- _ I-Outcome
stability -X- _ I-Outcome
in -X- _ I-Outcome
comparison -X- _ I-Outcome
with -X- _ I-Outcome
unmodified -X- _ I-Outcome
counterparts. -X- _ I-Outcome
CONCLUSION -X- _ O
: -X- _ O
Sequences -X- _ O
were -X- _ O
identified -X- _ O
within -X- _ O
the -X- _ O
highly -X- _ O
conserved -X- _ O
5 -X- _ O
( -X- _ O
′ -X- _ O
) -X- _ O
UTR -X- _ O
that -X- _ O
can -X- _ O
be -X- _ O
targeted -X- _ O
to -X- _ O
effectively -X- _ B-Outcome
inhibit -X- _ I-Outcome
EV71 -X- _ I-Outcome
replication -X- _ I-Outcome
through -X- _ I-Outcome
RNAi -X- _ I-Outcome
strategies. -X- _ I-Outcome
Appropriate -X- _ O
2 -X- _ O
( -X- _ O
′ -X- _ O
) -X- _ O
-modified -X- _ O
siRNAs -X- _ O
provide -X- _ O
a -X- _ O
promising -X- _ O
approach -X- _ O
to -X- _ O
optimizing -X- _ O
siRNAs -X- _ O
to -X- _ O
overcome -X- _ O
barriers -X- _ O
on -X- _ O
RNAi-based -X- _ O
antiviral -X- _ O
therapies -X- _ O
for -X- _ O
broader -X- _ O
administration -X- _ O
. -X- _ O

